Comment on AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know

AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know

For years, AbbVie's (NYSE: ABBV) powerhouse product Humira has held the top-dog position of best-selling drug in the world. In 2016, this anti-inflammatory drug brought in over $16 billion in global sales and is expected to remain the world's top-selling drug out to 2020.  However, being lead husky means the competition is always nipping at your heels, and competitors are itching to knock Humira off its perch.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News